Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop ...
The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.
Gold (XAU) hovers near $2,947 as Fed rate cut expectations rise. Silver (XAG) tests key levels amid trade tensions. Can bulls sustain momentum?
Pharmaceutical Technology on MSN1d
Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejectionEurope’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.
DAX dropped on March 11 amid tariff threats and economic uncertainty. Traders focus on fiscal stimulus, Fed policy, and US ...
Discover how outsourcing regulatory submission content development improves efficiency and ensures compliance.
Mía had dystrophic epidermolysis bullosa, better known as butterfly skin due to the extreme fragility of this tissue in ...
FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host confer ...
Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after receiving a negative opinion from the ...
The drug shortages are the result of manufacturing problems, increased demand, and other issues. View on euronews ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback